Rituximab + Cytotoxic Combination
Phase 2Completed 2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Behcet's Syndrome
Conditions
Behcet's Syndrome
Trial Timeline
Apr 1, 2006 → Jan 1, 2008
NCT ID
NCT00664599About Rituximab + Cytotoxic Combination
Rituximab + Cytotoxic Combination is a phase 2 stage product being developed by Roche for Behcet's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00664599. Target conditions include Behcet's Syndrome.
What happened to similar drugs?
0 of 1 similar drugs in Behcet's Syndrome were approved
Approved (0) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00664599 | Phase 2 | Completed |
Competing Products
2 competing products in Behcet's Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abatacept | Bristol Myers Squibb | Phase 1 | 29 |
| Placebo + Gevokizumab | XOMA | Phase 3 | 22 |